16 Dec
2020

Five key insights into 2020’s drug royalty transactions

Providing additional opportunities for the monetisation of life sciences IP, the drug royalty market continued to develop in 2020, producing a slew of new deals with creative and flexible structures

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth